Parvaneh Bahmani, MD
Nephrology · Los Angeles, CANPI 1609887678
Payments from drug & device makers
Across 493 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$3K
- Gilead$2K
- AstraZeneca$881
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$751
- Mallinckrodt Hospital Products Inc.$629
- Bayer$467
- plus $4K from 31 others
What the payments were for
- Speaking & faculty fees$180%
- Food & beverage$11,63598%
- Education$1812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 140 | $3,222 |
| Gilead | 84 | $1,988 |
| AstraZeneca(2 entities) | 33 | $881 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 55 | $751 |
| Mallinckrodt Hospital Products Inc. | 27 | $629 |
| Bayer | 25 | $467 |
| Amgen(2 entities) | 18 | $386 |
| Otsuka America Pharmaceutical, Inc. | 13 | $309 |
| Lilly USA, LLC | 13 | $300 |
| Boehringer Ingelheim | 7 | $288 |
| Outset Medical Inc | 1 | $261 |
| E.r. Squibb & Sons, L.L.C. | 4 | $260 |
| Novartis | 9 | $220 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $215 |
| EMD Serono, Inc. | 4 | $187 |
| Lexicon Pharmaceuticals, Inc. | 4 | $152 |
| Mylan Specialty L.p. | 8 | $151 |
| Shield Therapeutics Inc | 5 | $142 |
| Mallinckrodt Enterprises LLC | 5 | $119 |
| Nuwellis, Inc. | 1 | $118 |
| ANI Pharmaceuticals, Inc. | 3 | $100 |
| Calliditas Therapeutics US Inc. | 4 | $93 |
| GSK | 3 | $86 |
| Novo Nordisk | 4 | $82 |
| Merck | 4 | $81 |
| Ardelyx, Inc. | 2 | $68 |
| Amarin Pharma, Inc. | 2 | $46 |
| Pfizer | 2 | $45 |
| Altathera Pharmaceuticals LLC | 1 | $33 |
| Akebia Therapeutics Inc | 1 | $22 |
| Abbott | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Johnson & Johnson | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Napo Pharmaceuticals Inc | 1 | $18 |
| AbbVie | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,834 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SerostimSomatropin | 114 | $2,309,815 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 228 | $934,561 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 128 | $847,652 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 25 | $382,334 |
| CabenuvaCabotegravir/Rilpivirine | 35 | $249,348 |
| JardianceEmpagliflozin | 156 | $170,881 |
| DovatoDolutegravir Sodium/Lamivudine | 55 | $158,179 |
| JulucaDolutegravir/Rilpivirine | 37 | $126,681 |
| RukobiaFostemsavir Tromethamine | 13 | $117,725 |
| RelistorMethylnaltrexone Bromide | 55 | $110,575 |
| OzempicSemaglutide | 89 | $96,386 |
| FarxigaDapagliflozin Propanediol | 99 | $88,996 |
| EliquisApixaban | 98 | $80,829 |
| TrulicityDulaglutide | 58 | $65,029 |
| OtezlaApremilast | 11 | $51,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Serostim | $187 | $2,309,815114 claims |
| GileadBiktarvy | $1,988 | $934,561228 claims |
| Viiv Healthcare CompanyCabenuva, Dovato, Juluca, Rukobia, Triumeq | $3,222 | $698,661151 claims |
| PfizerOctagam, Eliquis | $45 | $463,163123 claims |
| Boehringer IngelheimJardiance, Tradjenta | $288 | $184,081175 claims |
| Novo NordiskOzempic, Wegovy | $82 | $120,858108 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $751 | $110,57555 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $300 | $97,68886 claims |
| AstraZenecaFarxiga | $881 | $88,99699 claims |
| AmgenOtezla | $386 | $51,69411 claims |
| NovartisEntresto | $220 | $28,76829 claims |
| AbbVieLinzess | $17 | $27,21240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.
Other nephrology in Los Angeles
- Anjay RastogiLos Angeles$6.3M
- Mohamed El-ShahawyLos Angeles$4.4M
- Suphamai BunnapradistLos Angeles$1.7M
- Victor CarabelloLos Angeles$1.4M
- John SimLos Angeles$1.3M
- Tariq ShahLos Angeles$1.2M
- Michael LevineLos Angeles$867K
- Aamir JamalSan Dimas$5.5M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.